Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17367279 | 0.85 | RAB9A (0.54) | AVPR1AHRH3AVPR2OXTR | |
| SCHEMBL6993813 | 0.84 | AVPR1A (0.59) | AVPR1AHRH3AVPR2OXTRSIGMAR1 | |
| SCHEMBL12548294 | 0.83 | HRH3 (0.48) | AVPR1AHRH3AVPR2OXTR | |
| Hydrochloric Acid SCHEMBL8012832 | 0.83 | AVPR1A (0.54) | AVPR1AHRH3AVPR2OXTRSIGMAR1 | |
| Hydrochloric Acid SCHEMBL8012830 | 0.82 | AVPR1A (0.53) | AVPR1AHRH3AVPR2OXTR | |
| SCHEMBL15963368 | 0.81 | ALDH1A1 (0.56) | AVPR1AHRH3OXTR | |
| SCHEMBL15963390 | 0.81 | AVPR1A (0.47) | AVPR1AHRH3AVPR2OXTR | |
| SCHEMBL15963372 | 0.81 | AVPR1A (0.54) | AVPR1AHRH3AVPR2OXTR | |
| SCHEMBL15963369 | 0.81 | ALDH1A1 (0.55) | AVPR1AHRH3 | |
| SCHEMBL15963358 | 0.81 | AVPR1A (0.52) | AVPR1AHRH3OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095068-A1 | AGENT FOR TREATING HCV INFECTION | EIF2AK2, IRF3, IFNAR1 | AVPR1A 3823/4885HRH3 3340/4885AVPR2 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.